Virtual biotechs a hit with investors and, increasingly, buyers

Biotech venture capitalists have increasingly embraced the virtual model, seeding companies with promising assets, tiny staffs and a willingness to outsource. Now, as Reuters notes, a recent Big Pharma buyout signals that the idea is gaining steam among larger players. XO1, an Index Ventures-backed virtual outfit, became Johnson & Johnson's ($JNJ) latest takeout target last month, is further affirmation that creating a small team devoted to a single asset can be the most efficient way to deploy cash in the biotech industry, according to some VCs. The XO1 exit follows a slew of similar deals, including Shire's ($SHPG) $325 million acquisition of FerroKin BioSciences, which had become a poster child for so-called backyard biotechs. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.